These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 22995303

  • 21. DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy.
    Ashwell S, Zabludoff S.
    Clin Cancer Res; 2008 Jul 01; 14(13):4032-7. PubMed ID: 18593978
    [Abstract] [Full Text] [Related]

  • 22. Targeting DNA repair as a promising approach in cancer therapy.
    Damia G, D'Incalci M.
    Eur J Cancer; 2007 Aug 01; 43(12):1791-801. PubMed ID: 17588740
    [Abstract] [Full Text] [Related]

  • 23. The HARP domain dictates the annealing helicase activity of HARP/SMARCAL1.
    Ghosal G, Yuan J, Chen J.
    EMBO Rep; 2011 Jun 01; 12(6):574-80. PubMed ID: 21525954
    [Abstract] [Full Text] [Related]

  • 24. DNA helicases as targets for anti-cancer drugs.
    Sharma S, Doherty KM, Brosh RM.
    Curr Med Chem Anticancer Agents; 2005 May 01; 5(3):183-99. PubMed ID: 15992349
    [Abstract] [Full Text] [Related]

  • 25. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target.
    Plummer R.
    Clin Cancer Res; 2010 Sep 15; 16(18):4527-31. PubMed ID: 20823148
    [Abstract] [Full Text] [Related]

  • 26. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
    Yap TA, Sandhu SK, Carden CP, de Bono JS.
    CA Cancer J Clin; 2011 Sep 15; 61(1):31-49. PubMed ID: 21205831
    [Abstract] [Full Text] [Related]

  • 27. Bis-benzimidazole anticancer agents: targeting human tumour helicases.
    Soderlind KJ, Gorodetsky B, Singh AK, Bachur NR, Miller GG, Lown JW.
    Anticancer Drug Des; 1999 Feb 15; 14(1):19-36. PubMed ID: 10363025
    [Abstract] [Full Text] [Related]

  • 28. Importance of DNA damage checkpoints in the pathogenesis of human cancers.
    Poehlmann A, Roessner A.
    Pathol Res Pract; 2010 Sep 15; 206(9):591-601. PubMed ID: 20674189
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Understanding DNA damage response and DNA repair pathways: applications to more targeted cancer therapeutics.
    Kinsella TJ.
    Semin Oncol; 2009 Apr 15; 36(2 Suppl 1):S42-51. PubMed ID: 19393835
    [Abstract] [Full Text] [Related]

  • 32. Targeting cell division cycle 7 kinase: a new approach for cancer therapy.
    Montagnoli A, Moll J, Colotta F.
    Clin Cancer Res; 2010 Sep 15; 16(18):4503-8. PubMed ID: 20647475
    [Abstract] [Full Text] [Related]

  • 33. Targeting the cell cycle: a new approach to cancer therapy.
    Schwartz GK, Shah MA.
    J Clin Oncol; 2005 Dec 20; 23(36):9408-21. PubMed ID: 16361640
    [Abstract] [Full Text] [Related]

  • 34. Defective replication stress response inhibits lymphomagenesis and impairs lymphocyte reconstitution.
    Puccetti MV, Fischer MA, Arrate MP, Boyd KL, Duszynski RJ, Bétous R, Cortez D, Eischen CM.
    Oncogene; 2017 May 04; 36(18):2553-2564. PubMed ID: 27797382
    [Abstract] [Full Text] [Related]

  • 35. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].
    Pourquier P, Pommier Y.
    Bull Cancer; 1998 Dec 04; Spec No():5-10. PubMed ID: 9932078
    [Abstract] [Full Text] [Related]

  • 36. Targeting homologous recombination repair defects in cancer.
    Evers B, Helleday T, Jonkers J.
    Trends Pharmacol Sci; 2010 Aug 04; 31(8):372-80. PubMed ID: 20598756
    [Abstract] [Full Text] [Related]

  • 37. [Cell cycle regulation after exposure to ionizing radiation].
    Teyssier F, Bay JO, Dionet C, Verrelle P.
    Bull Cancer; 1999 Apr 04; 86(4):345-57. PubMed ID: 10341340
    [Abstract] [Full Text] [Related]

  • 38. Molecular mechanisms of drug resistance.
    Longley DB, Johnston PG.
    J Pathol; 2005 Jan 04; 205(2):275-92. PubMed ID: 15641020
    [Abstract] [Full Text] [Related]

  • 39. Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair.
    Lin AB, McNeely SC, Beckmann RP.
    Clin Cancer Res; 2017 Jul 01; 23(13):3232-3240. PubMed ID: 28331049
    [Abstract] [Full Text] [Related]

  • 40. Repair and translesion DNA polymerases as anticancer drug targets.
    Maga G, Hübscher U.
    Anticancer Agents Med Chem; 2008 May 01; 8(4):431-47. PubMed ID: 18473728
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.